The new therapy of loss of pregnancy ~ Endothelial progenitor cells for vascular medicine and recombinant human soluble thrombomodulin
| Project/Area Number |
15K20168
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SANO Takumi 大阪医科大学, 医学部, 助教 (30817185)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 不育症 / 遺伝子組換え型ヒトトロンボモジュリン製剤 / リコモジュリン / 抗凝固療法 / sFlt-1 / preeclampsia / 妊娠高血圧腎症 / 習慣性流産 / 抗凝固薬 / ヘパリン / アスピリン / トロンボモジュリン / 不育症治療 / 死産 / 流産 / 生児獲得 / 流産マウス / 不育症マウス |
|---|
| Outline of Final Research Achievements |
Recombinant human Thrombomodulin(r-TM) as an anticoagulation therapy has the potential for the medical treatment of recurrent miscarriage and fetal growth restriction due to improved angiogenic factors. Additionally, r-TM treatment has the potential for the recovery of preeclampsia.
|
Report
(4 results)
Research Products
(1 results)
